Quarter ended 30th June, 2026

Date: 14th May 2026 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 531569 Sub: Investor Presentation for the First Quarter ended June 30, 2026. Dear Sir/ Madam, Please find enclosed herewith Investor Presentation of Sanjivani Paranteral Limited highlighting the performance of the Company during the First Quarter ended June 30, 2026. Kindly take the above information on your records. Thanking You, Yours Faithfully, For Sanjivani Paranteral Limited Ravikumar Bogam Company Secretary Cum Compliance Officer Investor Presentation Q1 FY27 Disclaimer This presentation and the accompanying slides (the Presentation), which have been prepared by Sanjivani Paranteral Ltd (Sanjivani, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. Investor Presentation SECTION 01 Company & Strategy 30+ Years 25 Countries 3 Verticals Company & Strategy A Diversified Pharmaceutical Company Combining Manufacturing Excellence, Export Capabilities And New About The Company Growth Verticals. Sanjivani Paranteral Ltd. is a Mumbai-headquartered pharmaceutical company with over 30+ years of experience in manufacturing high quality injectable and oral formulations. The Company operates four manufacturing facilities across India and Europe, including WHO- GMP, DIGEMID, and DDA-certified plants, serving customers in 25 countries through a strong export-oriented business. Execution Customer The Company caters to key therapeutic segments including CNS, Export-Led Innovation Quality Focus Excellence Centric cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti- allergics, supported by robust in-house R&D capabilities. Its diversified portfolio spans injectables, oral formulations, IV fluids, and nutraceuticals, strengthening its domestic presence and global footprint. Investor Presentation Company & Business — Key Facts & Figures 4 1,092 144 60 100+ sites Mn Mn Mn Annual Tablet + Capsule Annual Injectable Units IV Bottles/Yr — New Product Portfolio Mfg. Footprint Incl. Jv Units Capacity Capacity Pune Plant Business At A Glance Core products : Sterile injectables & oral solid dosages ROE : 14.3% Therapies : CNS, CVS, antibiotics, gastro, anti-diabetic ROCE : 17.0% Exports : 78.5% of FY26 revenue; 25 countries Book value : ₹41.39 CDMO : Contract manufacturing for injectables & orals Current Ratio : 2.24x IV fluids : SPL Infusion, Pune - Commercial manufacturing operations Debt to Equity: 0.19x Nutraceuticals : Alevia Healthcare JV, Prague (45% stake) Inventory Days : 3.95x Investor Presentation Company Journey — Three Decades of Building Capability 2026 • Established a multi-vertical growth 2023 platform • Expanded global footprint • Expanded across base business, IV fluids & through JV with Alevia nutraceuticals Healthcare S.R.O., Prague • Strengthened domestic presence through JV with Hindustan Antibiotics Ltd. 2009 • Acquisition of Dehradun manufacturing plant 2025 • Added oral solids manufacturing capacity • Commercial production commenced in Prague • Pune manufacturing plant commenced operations 2022 Expanded product portfolio to 100+ offerings 1996 • Navi Mumbai plant commissioned • Listed on BSE in April 1996 Investor Presentation Board & Key Management Mr. Ashwani Khemka Mr. Srivardhan Khemka Mr. Basant Srivastava Mr. Pritesh Jain Chairman & Executive Director Director Chief Financial Officer Managing Director With over 30 years of Leads the Company's Supports the Company's Leads the Company's experience in the operational and business strategic initiatives by finance function, pharmaceutical industry, Mr. development initiatives, overseeing governance, overseeing financial Khemka has been focusing on process regulatory compliance, and planning, capital instrumental in the optimization, operational operational functions, allocation, investor Company's growth, efficiency, market contributing to effective communication, and operational excellence, and expansion, and delivering business execution. corporate strategy while governance. affordable healthcare supporting business products growth. Investor Presentation SECTION 02 Business & Operations 4 1.24 Bn 78.5% Manufacturing Annual Export Facilities Capacity Revenue Business Structure — From a Single Engine to a Multi-Vertical Platform Injectables Orals (Tablets & Capsules) Nutraceuticals IV Fluids (New — Subsidiary) • Sterile liquid injectables, • Tablets, B-lactam tablets & • Domestic nutraceutical products • SPL Infusion Private Ltd, Pune ampoules & vials capsules • Prague JV builds a Europe • 60 Mn bottles/yr installed • CNS, CVS, antibiotics & anti- • Dossier filings to lift portfolio platform capacity emetics led breadth • 45% stake; majority under • Consolidated from Q3 FY26 • Pioneer heritage since 1996 • Dehradun-anchored capacity negotiation ₹110.12 Mn ₹84.13 Mn ₹0.18 Mn ₹43.81 Mn Q1 FY27 Revenue Q1 FY27 Revenue Q1 FY27 Revenue Q1 FY27 Revenue IV-fluid revenue of ~₹35 Mn over Dec 2025–Mar 2026 (~2 Mn bottles), consolidated in the SPL Infusion subsidiary; segment split above is standalone. Prague JV revenue (EUR 0.5–0.6 Mn, CY25) is not consolidated — Sanjivani holds 45%; profit share accrues from CY26. Investor Presentation Core Segments & CDMO Key Clients - Injectables, Orals & Nutraceuticals Segment revenue — FY25 vs FY26 (₹ Mn) Orals Grew +7.5% YoY FY25 FY26 412 Tablets rose to 43.1% of FY26 revenue (37.1% in FY25) as dossier approvals convert; Q4 tablets grew ~11.1% YoY even in a disrupted quarter. 279 Injectables Held The Anchor 53.5% of FY26 revenue; Q4 injectables (₹46.7 Mn) were hit by the March 2026 Middle East shipping disruption, not by demand. Mix Is Diver [Showing first 8,000 characters — download PDF for full document]